Most importantly, while the majority of clinical trials involving PD-L1/PD1 pathway inhibitors generally demonstrate an association between PD-L1 expression and clinical benefit from the drug, there is a great variability across the NSCLC studies with regard to medical applicability of observed findings (Table 1). The gene discussed is CD274; the disease is non-small cell lung carcinoma.